E-viri
-
Stölzel, Friedrich; Thiede, Christian; Rácil, Zdenek; Berdel, Wolfgang E; Kunzmann, Volker; Kroschinsky, Frank; Jöhrens, Korinna; Burchert, Andreas; Hochhaus, Andreas; Naumann, Ralph; Eckardt, Jan‑Niklas; Schetelig, Johannes; Einsele, Hermann; Kaiser, Ulrich; Krause, Stefan W; Mayer, Jiri; Kunadt, Desiree; Brümmendorf, Tim H; Bornhäuser, Martin; Röllig, Christoph; Krämer, Alwin; Herbst, Regina; Schäfer-Eckart, Kerstin; Scholl, Sebastian; Steffen, Björn; Müller‑Tidow, Carsten; Schliemann, Christoph; Wagenführ, Lisa; Serve, Hubert; Ehninger, Gerhard; Schaich, Markus; Neubauer, Andreas; Kuithan, Friederike; Baldus, Claudia D; Middeke, Jan Moritz; Hanoun, Maher; Stasik, Sebastian; Crysandt, Martina; Platzbecker, Uwe; Hänel, Mathias; Kaufmann, Martin
Dissertation
Background: Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML) and their impact on clinical outcomes is controversially discussed. - Methods: We retrospectively analyzed a large multi-center cohort of 1583 newly diagnosed AML patients, of whom 225 (14.21%) had EM. - Results: AML patients with EM presented with significantly higher counts of white blood cells (p < 0.0001), peripheral blood blasts (p < 0.0001), bone marrow blasts (p = 0.019), and LDH (p < 0.0001). Regarding molecular genetics, EM AML was associated with mutations of NPM1 (OR: 1.66, p < 0.001), FLT3-ITD (OR: 1.72, p < 0.001) and PTPN11 (OR: 2.46, p < 0.001). With regard to clinical outcomes, EM AML patients were less likely to achieve complete remissions (OR: 0.62, p = 0.004), and had a higher early death rate (OR: 2.23, p = 0.003). Multivariable analysis revealed EM as an independent risk factor for reduced overall survival (hazard ratio HR: 1.43, p < 0.001), however, for patients who received allogeneic hematopoietic cell transplantation (HCT) survival did not differ. For patients bearing EM AML, multivariable analysis unveiled mutated TP53 and IKZF1 as independent risk factors for reduced event-free (HR: 4.45, p < 0.001, and HR: 2.05, p = 0.044, respectively) and overall survival (HR: 2.48, p = 0.026, and HR: 2.63, p = 0.008, respectively). - Conclusion: Our analysis represents one of the largest cohorts of EM AML and establishes key molecular markers linked to EM, providing new evidence that EM is associated with adverse risk in AML and may warrant allogeneic HCT in eligible patients with EM.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.